JPWO2021184115A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021184115A5 JPWO2021184115A5 JP2022556099A JP2022556099A JPWO2021184115A5 JP WO2021184115 A5 JPWO2021184115 A5 JP WO2021184115A5 JP 2022556099 A JP2022556099 A JP 2022556099A JP 2022556099 A JP2022556099 A JP 2022556099A JP WO2021184115 A5 JPWO2021184115 A5 JP WO2021184115A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- therapeutically effective
- composition according
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 claims 1
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 229960004272 bucillamine Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991996P | 2020-03-19 | 2020-03-19 | |
| US62/991,996 | 2020-03-19 | ||
| PCT/CA2021/050350 WO2021184115A1 (en) | 2020-03-19 | 2021-03-16 | Use of bucillamine in the treatment of infectious diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518430A JP2023518430A (ja) | 2023-05-01 |
| JPWO2021184115A5 true JPWO2021184115A5 (https=) | 2024-02-02 |
| JP2023518430A5 JP2023518430A5 (https=) | 2024-02-02 |
Family
ID=77767915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556099A Pending JP2023518430A (ja) | 2020-03-19 | 2021-03-16 | 感染症の治療におけるブシラミンの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230172884A1 (https=) |
| EP (1) | EP4121035A4 (https=) |
| JP (1) | JP2023518430A (https=) |
| KR (1) | KR20230015320A (https=) |
| WO (1) | WO2021184115A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230172885A1 (en) * | 2020-05-13 | 2023-06-08 | The Regents Of The University Of California | Thiol-containing compounds for use in treating coronavirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025393A (en) * | 1995-09-25 | 2000-02-15 | Santen Pharmaceutical Co., Ltd. | Method for treatment of inflammatory intestinal diseases |
| WO2010014953A1 (en) * | 2008-08-01 | 2010-02-04 | The Regents Of The University Of Colorado, A Body Corporate | Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling |
| EP2528607A4 (en) * | 2010-01-28 | 2014-07-16 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR REVERSING A CORTICOSTEROID RESISTANCE OR TREATING RESPIRATORY RESPONSE |
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| GB201012889D0 (en) * | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| US9238018B2 (en) * | 2012-11-20 | 2016-01-19 | Revive Therapeutics Inc. | Use of bucillamine in the treatment of gout |
| JP7418958B2 (ja) * | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
-
2021
- 2021-03-16 WO PCT/CA2021/050350 patent/WO2021184115A1/en not_active Ceased
- 2021-03-16 US US17/912,597 patent/US20230172884A1/en active Pending
- 2021-03-16 JP JP2022556099A patent/JP2023518430A/ja active Pending
- 2021-03-16 EP EP21772039.0A patent/EP4121035A4/en not_active Withdrawn
- 2021-03-16 KR KR1020227036230A patent/KR20230015320A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058688A5 (https=) | ||
| JP2025013344A5 (https=) | ||
| JP2023002662A5 (https=) | ||
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2022191257A5 (https=) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| JP2006516570A5 (https=) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2005508840A5 (https=) | ||
| JP2005512995A5 (https=) | ||
| JP2005537268A5 (https=) | ||
| RU2002111657A (ru) | ГЕКСАГИДРОФУРО [2,3-b] ФУРАН-3-ИЛ-N-{3-[(1,3-БЕНЗОДИОКСОЛ-5-ИЛСУЛЬФОНИЛ) (ИЗОБУТИЛ) АМИНО]-1-БЕНЗИЛ-2-ГИДРОКСИПРОПИЛ} КАРБАМАТ КАК ИНГИБИТОР РЕТРОВИРУСНОЙ ПРОТЕАЗЫ | |
| JP2021529829A5 (https=) | ||
| JPWO2023054732A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2023055802A5 (https=) | ||
| JPWO2021184115A5 (https=) | ||
| JP2021512086A5 (https=) | ||
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| JP2008533079A5 (https=) | ||
| JP2019516722A (ja) | 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 | |
| KR20080028389A (ko) | 양극성 장애를 치료하기 위한 약제의 수득에 있어서의아고멜라틴의 용도 | |
| HUP0200655A2 (hu) | Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására | |
| JPWO2023165334A5 (https=) |